Nanobiotix (NBTX) Stock: Buy, Sell, or Hold?
NBTX - Nanobiotix S.A. American Depositary Shares
$29.19
3.36 (13.01%)
â˛
5d:
+31.31%
30d:
-17.17%
90d:
-26.47%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Sep 29, 2026
0d
Get Alerted When NBTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: NBTX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: NBTX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: NBTX is currently trading at $29.19, which is considered fair relative to its 30-day fair value range of $23.20 to $33.79. From a valuation perspective, the stock is trading at a discount (Forward PE: -195.5) compared to its historical average (178.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NBTX is in a downtrend. The price is approaching resistance at $29.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 13.0% recently.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $54.04 (+85.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NBTX is in a downtrend. The price is approaching resistance at $29.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 13.0% recently.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $54.04 (+85.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$23.20 -
$33.79
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.9%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (51/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+13.0%)
- BULLISH: Trading 85.1% below Wall St target ($54.04)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$23.20 -
$33.79
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$20.70
Resistance Level
$29.92
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-195.51
Wall Street Target
$54.04
(+85.1%)
Revenue Growth (YoY)
-79.2%
PE vs Historical
-195.5 vs 178.3
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 1:45 AM ET
Data refreshes hourly during market hours. Next update: 2:45 AM
Data refreshes hourly during market hours. Next update: 2:45 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 71 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
